Bordetella pertussis strains with increased toxin production associated with pertussis resurgence

Frits R Mooi, Inge H M van Loo, Marjolein van Gent, Qiushui He, Marieke J Bart, Kees J Heuvelman, Sabine C de Greeff, Dimitri Diavatopoulos, Peter Teunis, Nico Nagelkerke, Jussi Mertsola, Frits R Mooi, Inge H M van Loo, Marjolein van Gent, Qiushui He, Marieke J Bart, Kees J Heuvelman, Sabine C de Greeff, Dimitri Diavatopoulos, Peter Teunis, Nico Nagelkerke, Jussi Mertsola

Abstract

Before childhood vaccination was introduced in the 1940s, pertussis was a major cause of infant death worldwide. Widespread vaccination of children succeeded in reducing illness and death. In the 1990s, a resurgence of pertussis was observed in a number of countries with highly vaccinated populations, and pertussis has become the most prevalent vaccine-preventable disease in industrialized countries. We present evidence that in the Netherlands the dramatic increase in pertussis is temporally associated with the emergence of Bordetella pertussis strains carrying a novel allele for the pertussis toxin promoter, which confers increased pertussis toxin (Ptx) production. Epidemiologic data suggest that these strains are more virulent in humans. We discuss changes in the ecology of B. pertussis that may have driven this adaptation. Our results underline the importance of Ptx in transmission, suggest that vaccination may select for increased virulence, and indicate ways to control pertussis more effectively.

Figures

Figure 1
Figure 1
Alleles of pertussis toxin promoter (ptxP) observed worldwide. Bases are numbered –173 to +27 relative to the start of transcription (+1). The region to which 6 dimers of BvgA, the global regulator of B. pertussis virulence genes, bind is shaded. The –10 sequence motif and initiation codon are underlined. The DNA region –370 to –174, not shown here, was devoid of polymorphism. Locations of transcriptional signals and BvgA bindings sites are based on Bartoloni et al. (16).
Figure 2
Figure 2
Relationship between the emergence of pertussis toxin promoter 3 (ptxP3) strains and the epidemiology of pertussis in the Netherlands, 1989–2004. A) Temporal trends in the frequencies of ptxP3 strains and notifications. In this period 99% of the strains harbored either ptxP1 or ptxP3. B) Shift in age-specific distribution of notifications.
Figure 3
Figure 3
Production of pertussis toxin (Ptx) and pertactin (Prn) by pertussis toxin promoter 1 (ptxP1) and ptxP3 strains. Strains were incubated for the 48, 54, and 60 h, after which the amount of Ptx and Prn was determined by ELISA. The production ratio was calculated as follows: ptxP3 strain values/ptxP1 strain values; 8 strains, 4 ptxP1 strains and 4 ptxP3 strains, were used. The experiment was performed 3 times. Error bars indicate 95% confidence intervals. The Ptx and Prn ratios were significantly different from 1 (p<0.0001 and 0.03, respectively).

References

    1. Edwards KM, Decker MD. Pertussis vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: Saunders; 2004. p. 471–528.
    1. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect Dis. 2003;3:413–8. 10.1016/S1473-3099(03)00669-8
    1. de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis. 2000;6:348–57. 10.3201/eid0604.000404
    1. Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J. 2005;24(Suppl):S104–8. 10.1097/01.inf.0000166154.47013.47
    1. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect. 2006;53:106–13. 10.1016/j.jinf.2005.10.020
    1. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics. 2005;115:1422–7. 10.1542/peds.2004-2648
    1. Halperin SA. The control of pertussis—2007 and beyond. N Engl J Med. 2007;356:110–3. 10.1056/NEJMp068288
    1. Mooi FR, He Q, Guiso N. Phylogeny, evolution, and epidemiology of Bordetellae. In: Locht C, editor. Bordetella molecular microbiology, 1st ed. Norfolk (UK): Horizon Bioscience; 2007. p. 17–45.
    1. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun. 1998;66:670–5.
    1. Gzyl A, Augustynowicz E, Gniadek G, Rabczenko D, Dulny G, Slusarczyk J. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine. 2004;22:2122–8. 10.1016/j.vaccine.2003.12.006
    1. Fingermann M, Fernandez J, Sisti F, Rodriguez ME, Gatti B, Bottero D, et al. Differences of circulating Bordetella pertussis population in Argentina from the strain used in vaccine production. Vaccine. 2006;24:3513–21. 10.1016/j.vaccine.2006.02.026
    1. Watanabe M, Nagai M. Effect of acellular pertussis vaccine against various strains of Bordetella pertussis in a murine model of respiratory infection. J Health Sci. 2002;48:560–4. 10.1248/jhs.48.560
    1. King AJ, Berbers G, van Oirschot HF, Hoogerhout P, Knipping K, Mooi FR. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology. 2001;147:2885–95.
    1. Verwey W, Thiele E, Sage D, Suchardt L. A simplified liquid culture medium for the growth of Haemophilus pertussis. J Bacteriol. 1949;58:127–34.
    1. Hijnen M, He Q, Schepp R, van Gageldonk P, Mertsola J, Mooi FR, et al. Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin. Scand J Infect Dis. 2008;40:94–104. 10.1080/00365540701642138
    1. Bartoloni A, Pizza M, Bigio M, Nucci D, Ashworth LA, Irons LI, et al. Mapping of a protective epitope of pertussis toxin by in vitro refolding of recombinant fragments. Bio/Technology. 1988;6:709–12. 10.1038/nbt0688-709
    1. Hewlett EL, Donato GM. Bordetella toxins. In: Locht C, editor. Bordetella molecular microbiology. Norfolk (UK): Horizon Bioscience; 2007. p. 97–118.
    1. Stibitz S. The bvg regulon. In: Locht C, editor. Bordetella molecular microbiology. Norfolk (UK): Horizon Bioscience; 2007. p. 47–67.
    1. van Loo IH, Heuvelman KJ, King AJ, Mooi FR. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol. 2002;40:1994–2001. 10.1128/JCM.40.6.1994-2001.2002
    1. Diavatopoulos DA, Cummings CA, Schouls LM, Brinig MM, Relman DA, Mooi FR. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog. 2005;1:e45. 10.1371/journal.ppat.0010045
    1. Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, Harris DE, et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica. Nat Genet. 2003;35:32–40. 10.1038/ng1227
    1. Hallander H, Advani A, Riffelmann M, vonKonig CHW, Caro V, Guiso N, et al. Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol. 2007;45:3257–62. 10.1128/JCM.00864-07
    1. Elomaa A, Advani A, Donnelly D, Antila M, Mertsola J, He Q, et al. Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories. Vaccine. 2007;25:918–26. 10.1016/j.vaccine.2006.09.012
    1. Carbonetti NH, Artamonova GV, Van Rooijen N, Ayala VI. Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract. Infect Immun. 2007;75:1713–20. 10.1128/IAI.01578-06
    1. Kirimanjeswara GS, Agosto LM, Kennett MJ, Bjornstad ON, Harvill ET. Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest. 2005;115:3594–601. 10.1172/JCI24609
    1. Mielcarek N, Riveau G, Remoue F, Antoine R, Capron A, Locht C. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat Biotechnol. 1998;16:454–7. 10.1038/nbt0598-454
    1. King AJ, van Gorkom T, Pennings JL, van der Heide HG, He Q, Diavatopoulos D, et al. Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics. 2008;9:311. 10.1186/1471-2164-9-311
    1. Watanabe M, Nagai M. Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert Rev Anti Infect Ther. 2004;2:447–54. 10.1586/14787210.2.3.447
    1. Pierce C, Klein N, Peters M. Is leukocytosis a predictor of mortality in severe pertussis infection? Intensive Care Med. 2000;26:1512–4. 10.1007/s001340000587
    1. Advani A, Gustafsson L, Carlsson RM, Donnelly D, Hallander HO. Clinical outcome of pertussis in Sweden: association with pulsed-field gel electrophoresis profiles and serotype. APMIS. 2007;115:736–42. 10.1111/j.1600-0463.2007.apm_628.x
    1. Van Buynder PG, Owen D, Vurdien JE, Andrews NJ, Matthews RC, Miller E. Bordetella pertussis surveillance in England and Wales: 1995–7. Epidemiol Infect. 1999;123:403–11. 10.1017/S0950268899003052
    1. Preziosi MP, Yam A, Wassilak SG, Chabirand L, Simaga A, Ndiaye M, et al. Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. Am J Epidemiol. 2002;155:891–6. 10.1093/aje/155.10.891
    1. Davison F, Nair V. Use of Marek’s disease vaccines: could they be driving the virus to increasing virulence? Expert Rev Vaccines. 2005;4:77–88. 10.1586/14760584.4.1.77
    1. Best SM, Kerr PJ. Coevolution of host and virus: the pathogenesis of virulent and attenuated strains of myxoma virus in resistant and susceptible European rabbits. Virology. 2000;267:36–48. 10.1006/viro.1999.0104
    1. Mackinnon MJ, Read AF. Immunity promotes virulence evolution in a malaria model. PLoS Biol. 2004;2:E230. 10.1371/journal.pbio.0020230
    1. Gandon S, Mackinnon MJ, Nee S, Read AF. Imperfect vaccines and the evolution of pathogen virulence. Nature. 2001;414:751–6. 10.1038/414751a
    1. Taranger J, Trollfors B, Bergfors E, Knutsson N, Sundh V, Lagergard T, et al. Mass vaccination of children with pertussis toxoid – decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis. 2001;33:1004–10. 10.1086/322639
    1. Luttinger P. The epidemiology of pertussi. Am J Dis Child. 1916;12:290–315.

Source: PubMed

3
Suscribir